Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance

Eur Thyroid J. 2022 Sep 27;11(5):e220044. doi: 10.1530/ETJ-22-0044. Print 2022 Oct 1.

Authors

Ségolène Hescot¹, Julien Masliah-Planchon², Pauline du Rusquec¹, Célia Dupain¹, Maud Kamal¹, Vincent Servois³, Ivan Bieche²

Affiliations

¹ Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
² Department of Genetics, Institut Curie, Paris, France.
³ Department of Radiology, Institut Curie, Paris, France.

No abstract available

Publication types

Case Reports